EGFR expression

Initial data suggest that BLU-451 is an active molecule. Further evaluation of the safety profile and pharmacokinetic properties of BLU-451 is needed.

Experimentally, PPRE reduced CRC cell viability and downregulated STAT3, EGFR, SRC, IL-6, and AKT1 expression. These findings suggest that P. polyphylla exerts anticancer effects through the coordinated modulation of multiple oncogenic pathways in CRC.

P2, N=40, Recruiting, Eye & ENT Hospital of Fudan University | Not yet recruiting --> Recruiting

P2, N=104, Recruiting, Fudan University | Suspended --> Recruiting

We identified CASK as a previously unrecognized driver of NSCLC growth and a potential prognostic biomarker. By regulating EGFR trafficking to late endosomes and attenuating AKT and ERK signaling, CASK suppresses p21 expression and promotes NSCLC cell proliferation, revealing a novel proliferation regulator in NSCLC.

Our study revealed that TGM2 is a potential therapeutic target or biomarker for predicting acquired EGFR-TKI resistance in EGFR-mutated NSCLC.

This study identifies bulk transcriptome-defined groups and reveals EGFR-associated malignant cell programs linked to distinct microenvironmental interaction patterns. The EGFR-high malignant cell state features proliferative and angiogenic programs, while the EGFR-low malignant cell state shows enhanced immune infiltration. These findings provide molecular evidence for precision classification and subtype-specific therapeutic strategies.

P1, N=80, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting

Further studies investigating the draining lymph node dendritic cells (DCs) indicate that the destruction of cetuximab-coated tumor cells by G47Δ promotes uptake of tumor cells by DCs, enhances the priming of immune responses, and subsequently stimulates tumor-specific CD8+ T cells. These results suggest that the combination of G47Δ therapy and molecular targeted therapies with ADCC activity may represent a useful therapeutic strategy for enhancing antitumor immune responses, even after the emergence of acquired resistance.

In conclusion, rLj-RGD4 exerts potent in vivo antitumor activity via two mechanisms: induction of multi-pathway apoptosis and EGFR-targeted suppression of pro-survival signaling. RGD4 exerts its antitumor function in vivo by targeting and co-internalizing with EGFR.

Furthermore, PA was validated in vitro to upregulate FABP6 and downregulate EGFR expression and suppress the bladder cancer progression in vivo. PA, the active ingredient of GLQMW, can inhibit BC by inhibiting EGFR and upregulating FABP6.

Western blotting confirmed significant differential expression of EGFR, p85α, and HSP90β proteins in tumor tissues from protamine-treated versus model groups. This study concludes that carp protamine is a natural macromolecule exhibiting anti-liver cancer effects, whose enzymatically derived peptides induce apoptosis in liver cancer cells through multi-target regulatory mechanisms.